Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo aims to boost immune attack on tough head & neck cancers

NCT ID NCT05061420

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding an experimental drug called SAR444245 to standard cancer treatments could help people with advanced head and neck cancer. It involved 59 adults whose cancer had returned or spread. The goal was to see if the combination led to more tumor shrinkage than expected from standard treatments alone. The study was terminated early, and its results are not yet publicly known.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope- Site Number : 8400007

    Duarte, California, 91010, United States

  • Investigational Site Number : 0320001

    Buenos Aires, 1012, Argentina

  • Investigational Site Number : 1240001

    Montreal, Quebec, H4A 3J1, Canada

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 8420383, Chile

  • Investigational Site Number : 1520002

    Temuco, 4800827, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, 7500921, Chile

  • Investigational Site Number : 1520004

    Viña del Mar, Región de Valparaíso, 2540488, Chile

  • Investigational Site Number : 1580003

    Tainan, 704, Taiwan

  • Investigational Site Number : 2500001

    Villejuif, 94800, France

  • Investigational Site Number : 2500002

    Strasbourg, 67033, France

  • Investigational Site Number : 2500003

    Bordeaux, 33075, France

  • Investigational Site Number : 2500006

    Paris, 75015, France

  • Investigational Site Number : 2500008

    Lyon, 69008, France

  • Investigational Site Number : 2760004

    Berlin, 12200, Germany

  • Investigational Site Number : 3800003

    Brescia, 25123, Italy

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, 06351, South Korea

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, 05505, South Korea

  • Investigational Site Number : 5280001

    Nijmegen, 6500 HB, Netherlands

  • Investigational Site Number : 5280002

    Amsterdam, 1066, Netherlands

  • Investigational Site Number : 7240001

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7240003

    Madrid, Madrid, Comunidad de, 28046, Spain

  • Investigational Site Number : 7240004

    Barcelona, Barcelona [Barcelona], 08036, Spain

  • Investigational Site Number : 7240005

    Madrid, Madrid, Comunidad de, 28040, Spain

  • Seattle Cancer Care Alliance Site Number : 8400006

    Seattle, Washington, 98115, United States

  • Thomas Jefferson University Hospital Site Number : 8400003

    Philadelphia, Pennsylvania, 19107, United States

  • University of Colorado- Site Number : 8400004

    Aurora, Colorado, 80045, United States

  • University of Michigan- Site Number : 8400008

    Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

SQUAMOUS CELL CARCINOMA OF HEAD AND NECK